GlaxoSmithKline Inc
Registered Principal Details
Business Or Interest:
Pharmaceutical Manufacturer.
Lobbying Interests:
Lobby areas of healthcare, wellness, and pharmaceutical issues.
CEO Name:
Andrew Witty
Director, State Government Affairs
Pharmaceutical Manufacturer.
Lobbying Interests:
Lobby areas of healthcare, wellness, and pharmaceutical issues.
CEO Name:
Andrew Witty
Director, State Government Affairs
Contact
SB
Sandie Benen
47 W. Division Street, #234
Chicago, IL 60610
(312) 504-4080
(312) 335-9821
sandra.e.benen@gsk.com
http://www.gsk.com
47 W. Division Street, #234
Chicago, IL 60610
(312) 504-4080
(312) 335-9821
sandra.e.benen@gsk.com
http://www.gsk.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 19
Relating to: torts and personal injury trusts. (FE)
Bill Text and History
2013 Wisconsin Act 154
3/3/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: torts and personal injury trusts. (FE)
Bill Text and History
2013 Wisconsin Act 154
For
Notification Date3/3/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 27
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
Bill Text and History
2013 Wisconsin Act 105
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
Bill Text and History
2013 Wisconsin Act 105
For
Notification Date4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 392
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
Bill Text and History
9/30/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
Bill Text and History
For
Notification Date9/30/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Assembly Bill 656
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
Bill Text and History
2/6/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
GSK supports AA1
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
Bill Text and History
Other
Notification Date2/6/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
GSK supports AA1
Senate Bill 19
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
Bill Text and History
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
Bill Text and History
For
Notification Date4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 300
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
Bill Text and History
2013 Wisconsin Act 186
9/26/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
Bill Text and History
2013 Wisconsin Act 186
For
Notification Date9/26/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 498
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
Bill Text and History
2013 Wisconsin Act 339
2/6/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
GSK supports SA1
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
Bill Text and History
2013 Wisconsin Act 339
Other
Notification Date2/6/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
GSK supports SA1
Senate Joint Resolution 87
Relating to: Chronic Obstructive Pulmonary Disease Awareness Month.
Bill Text and History
3/14/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: Chronic Obstructive Pulmonary Disease Awareness Month.
Bill Text and History
For
Notification Date3/14/2014
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Budget Bill Subjects
Biennial budget bill treatment of matter relating to
Health Services: Medical Assistance and Related Programs -- Benefits
Health Services: Medical Assistance and Related Programs -- Benefits
Notification Date
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Medicaid funding
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Comments
Medicaid funding
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Transparency in private attorney contracting.
Transparency in private attorney contracting.
Action Intended To Affect
Legislative matter
Notification Date
7/30/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Legislative matter
Notification Date
7/30/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
oral chemotherapy
oral chemotherapy
Action Intended To Affect
Both Legislative matter and rule
Notification Date
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
4/9/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Medicaid funding
Medicaid funding
Action Intended To Affect
Both Legislative matter and rule
Notification Date
3/8/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
3/8/2013
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2013 January - June $22,150.00 |
2013 July - December $22,864.00 |
2014 January - June $14,162.25 |
2014 July - December $1,901.25 |
Total $61,077.50 |
| Total Hours Communicating | 2013 January - June 27.75 |
2013 July - December 28.75 |
2014 January - June 13.00 |
2014 July - December 2.00 |
Total 71.50 |
| Total Hours Other | 2013 January - June 65.75 |
2013 July - December 66.25 |
2014 January - June 71.00 |
2014 July - December 5.50 |
Total 208.50 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 5% |
2013 July - December 15% |
2014 January - June |
2014 July - December |
Total 7% |
Relating to: state agencies entering into contracts for legal services on a contingent fee basis. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 5% |
2013 July - December 15% |
2014 January - June |
2014 July - December |
Total 7% |
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December 20% |
2014 January - June 20% |
2014 July - December |
Total 13% |
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December 20% |
2014 January - June 35% |
2014 July - December |
Total 17% |
Relating to: torts and personal injury trusts. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December |
2014 January - June 5% |
2014 July - December |
Total 1% |
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December |
2014 January - June 10% |
2014 July - December |
Total 3% |
Relating to: notifications concerning the assertion of rights under a patent or pending patent and providing a penalty. (FE)
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December |
2014 January - June 10% |
2014 July - December |
Total 3% |
Relating to: Chronic Obstructive Pulmonary Disease Awareness Month.
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June |
2013 July - December |
2014 January - June 10% |
2014 July - December 20% |
Total 4% |
Budget Bill Subjects
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 10% |
2013 July - December |
2014 January - June |
2014 July - December |
Total 3% |
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 20% |
2013 July - December 10% |
2014 January - June |
2014 July - December |
Total 10% |
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 20% |
2013 July - December |
2014 January - June |
2014 July - December |
Total 7% |
| 2013 January - June |
2013 July - December |
2014 January - June |
2014 July - December |
Total |
|---|---|---|---|---|
| 2013 January - June 30% |
2013 July - December 20% |
2014 January - June |
2014 July - December |
Total 17% |
Minor Efforts
(Time spent on matters each of which accounted for less than 10% of the organization's lobbying.)
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication